Nandrolone

Summary

Nandrolone (CHEMBL757) is a phase-3 clinical-stage small molecule targeting AR; indicated across 1 condition including aplastic anemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (AR)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 274.4 Da · C18H26O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL757
Name	Nandrolone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9904
ChEBI	CHEBI:7466
Molecular formula	C18H26O2
Molecular weight	274.4
InChIKey	NPAGDVCDWIYMMC-IZPLOLCNSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34

IUPAC name: (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one

ChEBI definition: A 3-oxo Δ4-steroid that is estr-4-en-3-one substituted by a β-hydroxy group at position 17.

Other ChEBI roles (chemical / environmental): human metabolite.

Also known as: Biobol, Decadura, Hybolin, Menidrabol, Nandrolone, Nandrolone ciii, NSC-3351, nandrolon, nandrolone, SID29215354, SID85148374, SID144206718

Parent form; salt/anhydrous children: CHEMBL3337497

Patent coverage: 2,650 distinct patent families (9,485 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
AR	Androgen receptor	Agonist			P10275

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Thyroid hormone receptor beta, Corticosteroid-binding globulin, Androgen receptor, Sex hormone-binding globulin, Aldehyde dehydrogenase 1A1, Solute carrier family 22 member 1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 7 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P15207	8.68	Ki	2.1	nM	CHEMBL_ACT_7731043
P15207	8.5	IC50	3.15	nM	CHEMBL_ACT_7731042
SHBG	6.3	Kd	501.2	nM	CHEMBL_ACT_2155683
SERPINA6	6.14	Ki	724.4	nM	CHEMBL_ACT_953950

Target pathways

Aggregated over 1 target gene(s): AR.

Top Reactome pathways

23 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	1	AR
Signaling by Rho GTPases	1	AR
RHO GTPase Effectors	1	AR
Generic Transcription Pathway	1	AR
Cellular responses to stress	1	AR
SUMOylation	1	AR
SUMO E3 ligases SUMOylate target proteins	1	AR
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	1	AR
Nuclear Receptor transcription pathway	1	AR
Metabolism of proteins	1	AR
SUMOylation of intracellular receptors	1	AR
RHO GTPases activate PKNs	1	AR
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3	1	AR
Deubiquitination	1	AR
Ub-specific processing proteases	1	AR
Post-translational protein modification	1	AR
RNA Polymerase II Transcription	1	AR
Gene expression (Transcription)	1	AR
Transcriptional regulation by RUNX2	1	AR
RUNX2 regulates osteoblast differentiation	1	AR
RUNX2 regulates bone development	1	AR
Cellular responses to stimuli	1	AR
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1	AR

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	1
MAPK cascade	1
in utero embryonic development	1
regulation of systemic arterial blood pressure	1
epithelial cell morphogenesis	1
transcription by RNA polymerase II	1
signal transduction	1
cell-cell signaling	1
spermatogenesis	1
single fertilization	1
positive regulation of cell population proliferation	1
negative regulation of cell population proliferation	1
male gonad development	1
positive regulation of gene expression	1
male somatic sex determination	1

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
aplastic anemia	3	MONDO:0015909	HP:0001915

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000597	PHASE3	COMPLETED	Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

130 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
MEGESTROL	ChEMBL + PubChem	Phase 4 (approved)	AR
ABIRATERONE	ChEMBL	Phase 4 (approved)	AR
APALUTAMIDE	ChEMBL	Phase 4 (approved)	AR
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	AR
BECLOMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	AR
BETAMETHASONE	ChEMBL	Phase 4 (approved)	AR
BICALUTAMIDE	ChEMBL	Phase 4 (approved)	AR
BITHIONOL	ChEMBL	Phase 4 (approved)	AR
BROMHEXINE	ChEMBL	Phase 4 (approved)	AR
BUDESONIDE	ChEMBL	Phase 4 (approved)	AR
CHLORMADINONE	ChEMBL	Phase 4 (approved)	AR
CLARITHROMYCIN	ChEMBL	Phase 4 (approved)	AR
CLASCOTERONE	ChEMBL	Phase 4 (approved)	AR
CLOCORTOLONE PIVALATE	ChEMBL	Phase 4 (approved)	AR
CLOMIPHENE	ChEMBL	Phase 4 (approved)	AR
CORTISONE	ChEMBL	Phase 4 (approved)	AR
CYCLOFENIL	ChEMBL	Phase 4 (approved)	AR
DAROLUTAMIDE	ChEMBL	Phase 4 (approved)	AR
DESOGESTREL	ChEMBL	Phase 4 (approved)	AR
DESOXIMETASONE	ChEMBL	Phase 4 (approved)	AR
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	AR
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	AR
DIFLORASONE DIACETATE	ChEMBL	Phase 4 (approved)	AR
DORZOLAMIDE	ChEMBL	Phase 4 (approved)	AR
DROSPIRENONE	ChEMBL	Phase 4 (approved)	AR
DYDROGESTERONE	ChEMBL	Phase 4 (approved)	AR
ENZALUTAMIDE	ChEMBL	Phase 4 (approved)	AR
EPLERENONE	ChEMBL	Phase 4 (approved)	AR
ESTRADIOL	ChEMBL	Phase 4 (approved)	AR
ESTRADIOL CYPIONATE	ChEMBL	Phase 4 (approved)	AR
ESTRADIOL VALERATE	ChEMBL	Phase 4 (approved)	AR
ESTRIOL	ChEMBL	Phase 4 (approved)	AR
ESTRONE	ChEMBL	Phase 4 (approved)	AR
ETHINYL ESTRADIOL	ChEMBL	Phase 4 (approved)	AR
ETHYNODIOL DIACETATE	ChEMBL	Phase 4 (approved)	AR
ETONOGESTREL	ChEMBL	Phase 4 (approved)	AR
FLUMETHASONE PIVALATE	ChEMBL	Phase 4 (approved)	AR
FLUOCINOLONE ACETONIDE	ChEMBL	Phase 4 (approved)	AR
FLUOCINONIDE	ChEMBL	Phase 4 (approved)	AR
FLUOXYMESTERONE	ChEMBL	Phase 4 (approved)	AR
FLURANDRENOLIDE	ChEMBL	Phase 4 (approved)	AR
FLUTAMIDE	ChEMBL	Phase 4 (approved)	AR
FLUTICASONE FUROATE	ChEMBL	Phase 4 (approved)	AR
FLUTICASONE PROPIONATE	ChEMBL	Phase 4 (approved)	AR
HALCINONIDE	ChEMBL	Phase 4 (approved)	AR
HALOBETASOL PROPIONATE	ChEMBL	Phase 4 (approved)	AR
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	AR
HEXESTROL	ChEMBL	Phase 4 (approved)	AR
HYDROCORTISONE	ChEMBL	Phase 4 (approved)	AR
INDOMETHACIN	ChEMBL	Phase 4 (approved)	AR
LEVONORGESTREL	ChEMBL	Phase 4 (approved)	AR
MEDROXYPROGESTERONE	ChEMBL	Phase 4 (approved)	AR
METHYLPREDNISOLONE	ChEMBL	Phase 4 (approved)	AR
MIFEPRISTONE	ChEMBL	Phase 4 (approved)	AR
MOMETASONE FUROATE	ChEMBL	Phase 4 (approved)	AR
NILUTAMIDE	ChEMBL	Phase 4 (approved)	AR
NOMEGESTROL	ChEMBL	Phase 4 (approved)	AR
NORETHINDRONE	ChEMBL	Phase 4 (approved)	AR
NORETHYNODREL	ChEMBL	Phase 4 (approved)	AR
OXANDROLONE	ChEMBL	Phase 4 (approved)	AR
OXICONAZOLE	ChEMBL	Phase 4 (approved)	AR
PRANLUKAST	ChEMBL	Phase 4 (approved)	AR
PRASUGREL	ChEMBL	Phase 4 (approved)	AR
PREDNISOLONE	ChEMBL	Phase 4 (approved)	AR
PROGESTERONE	ChEMBL	Phase 4 (approved)	AR
PYRVINIUM	ChEMBL	Phase 4 (approved)	AR
RIFAPENTINE	ChEMBL	Phase 4 (approved)	AR
SERTACONAZOLE	ChEMBL	Phase 4 (approved)	AR
SPIRONOLACTONE	ChEMBL	Phase 4 (approved)	AR
STIRIPENTOL	ChEMBL	Phase 4 (approved)	AR
TESTOSTERONE	ChEMBL	Phase 4 (approved)	AR
TESTOSTERONE PROPIONATE	ChEMBL	Phase 4 (approved)	AR
TRETINOIN	ChEMBL	Phase 4 (approved)	AR
TROGLITAZONE	ChEMBL	Phase 4 (approved)	AR
ULIPRISTAL	ChEMBL	Phase 4 (approved)	AR
ASOPRISNIL	ChEMBL	Phase 3	AR
CYPROTERONE	ChEMBL	Phase 3	AR
ENOBOSARM	ChEMBL	Phase 3	AR
ETHISTERONE	ChEMBL	Phase 3	AR
GALETERONE	ChEMBL	Phase 3	AR
GESTODENE	ChEMBL	Phase 3	AR
GOSSYPOL	ChEMBL	Phase 3	AR
TIRATRICOL	ChEMBL	Phase 3	AR
TIRILAZAD	ChEMBL	Phase 3	AR
ALLYLESTRENOL	ChEMBL	Phase 2	AR
BENTAZEPAM	ChEMBL	Phase 2	AR
CIFENLINE	ChEMBL	Phase 2	AR
CLOFOCTOL	ChEMBL	Phase 2	AR
DICHLORISONE	ChEMBL	Phase 2	AR
DIOXYBENZONE	ChEMBL	Phase 2	AR
FLAVONE	ChEMBL	Phase 2	AR
FLUMETHASONE	ChEMBL	Phase 2	AR
FLUOCORTIN BUTYL	ChEMBL	Phase 2	AR
GUMELUTAMIDE	ChEMBL	Phase 2	AR
HALOMETASONE	ChEMBL	Phase 2	AR
HYDROCORTISONE ACEPONATE	ChEMBL	Phase 2	AR
HYDROXYFLUTAMIDE	ChEMBL	Phase 2	AR
LONAPRISAN	ChEMBL	Phase 2	AR
METRIBOLONE	ChEMBL	Phase 2	AR
MK-0773	ChEMBL	Phase 2	AR